Patent ID: 11944612
Assignee: GLOBAL BLOOD THERAPEUTICS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 18:
19. The method of claim 10, wherein the crystalline ansolvate form of Compound 1 is substantially free of Form I and/or Form N; wherein Form I is characterized by at least three X-ray powder diffraction peaks (Cu Ka radiation) selected from 12.820, 15.740, 16.030, 16.630, 17.600, 25.140, 25.820 and 26.44020 (each ±0.2 020); and wherein Form N is characterized by at least three X-ray powder diffraction peaks (Cu Ka radiation) selected from 11.65°, 11.850, 12.080, 16.700, 19.65″ and 23.48° 20 (each ±0.2 20).